Patients with schizophrenia or a mood disorder who switched antipsychotic treatment had an increased likelihood for relapse, healthcare resource utilization, and extrapyramidal symptoms.
Nutrient supplements had good safety profiles, no known contraindications with psychiatric medications.
Researchers found data that showed, after a 10-year period, a slight decline for the intelligence quotient of patients with schizophrenia.
Individuals with pediatric-onset bipolar disorder fare better than individuals diagnosed at a later age with the disorder, and bipolar disorder in general is associated with better outcomes than schizophrenia.
Findings showed a higher incidence of hyperglycemic episodes in patients with diabetes and comorbid schizophrenia than in those without schizophrenia.
A lack of belief in the value of medication and the number of previous hospitalizations also predict hospitalization in first-episode psychosis.
Abnormal neuropsychiatric genetic variants should not be assumed to have an etiologic role if observed in a patient with schizophrenia.
Generalized fractional anisotropy reductions in bundles connecting regions involved in mood regulation and motor function were seen in patients with schizophrenia and bipolar disorder.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia.
Patients with schizophrenia who participated in a telephone intervention problem-solving program were found to have higher rates of medication adherence compared with patients who received routine hospital care for schizophrenia.
